ENTECAVIR IN THE TREATMENT OF REACTIVATION OF HEPATITIS B VIRUS INFECTION IN CHEMOTHERAPY FOR B-CELL LYMPHOMA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Manifest or occult (latent) hepatitis B virus (HBV) infection is a serious problem for patients with blood cancers during chemotherapy. All clinicians involved in the treatment of malignant tumors must carry out HBV infection screening in a group of patients with malignant blood diseases and a risk for reactivation of virus infection. The paper describes a clinical case of the reactivation of HBV infection in a female patient with B-cell lymphoma and evolving liver cell failure, which could be eliminated with nucleoside analogues. It also discusses procedures to prevent and treat reactivation of HBV infection in B-cell lymphoma patients receiving chemotherapy.

Full Text

Restricted Access

About the authors

T. N LOPATKINA

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

Email: lopatkina-tn@mail.ru
Academician of the Russian Academy of Sciences and the Russian Academy of Medical Sciences N.A. Mukhin's Academic Group

D. T ABDURAKHMANOV

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

Academician of the Russian Academy of Sciences and the Russian Academy of Medical Sciences N.A. Mukhin's Academic Group

E. V VOLCHKOVA

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

Academician of the Russian Academy of Sciences and the Russian Academy of Medical Sciences N.A. Mukhin's Academic Group

E. L TANASHCHUK

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia

Academician of the Russian Academy of Sciences and the Russian Academy of Medical Sciences N.A. Mukhin's Academic Group

References

  1. Wands J.R., Chura C.M., Roll F.J., Maddrey W.C. Serial studies of hepatitis- associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-112.
  2. Galbraith R.M., Eddleston A.L.W.F., Williams R. et al. Fulminant hepaticfailure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 1975; 2: 528-530.
  3. Vento S., Cainelli F., Longhi M.S. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncology 2002; 3: 333-340.
  4. Мухин H.A., Абдурахманов Д.Т., Лопаткина T.H. Реактивация хронической HBV-инфекции: основные причины, профилактика и лечение. Практикующий врач 2004; 1: 2-5.
  5. Абдурахманов Д.Т. Противовирусная терапия хронического гепатита В. Клин. фармакология и терапия 2004; 13(1): 13-18.
  6. Абдурахманов Д.Т. Хронический гепатит В и D. М.: ГЭОТАР-Медиа, 2010.
  7. Li H.R., Huang J.J., Guo H.Q. et al. Comparison of entecavir and lamivudin in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J. Viral Hepatitis 2010; doi: 10.1111/j.1362-2893.2010.01386.x
  8. Ferreira R., Carvalheiro J., Torres J. et al. Fatal Hepatitis B Reactivation Treated With Entecavir in an Isolated Anti-HBs Positive Lymphoma Patient: A Case Report and Literature Review. Saudi J. Gastroeterol. 2012; 18 (4): 277-281.
  9. Маевская М.В., Буеверов А.Ю. Энтекавир - новое в лечении больных хроническим гепатитом В. Клинические перспективы гастроэнтерологии, гепатологии 2007; 2: 1-6.
  10. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
  11. Torres H.A., Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nature Rev. Clin. Oncol. 2012; 9: 156-166.
  12. Raimondo G., Pollicino T., Cacciola I. et al. Occult hepatitis B virus infection. J. Hepatol. 2007; 46: 160-170.
  13. Abdelmalek M.F., Pasha T.M., Zein N.N. et al. Subclinical reactivation of hepatitis B virus in liver transplantat recipients with past exposure. Liver Transpl. 2003; 9: 1253-1257.
  14. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br. J. Haematol. 2007; 136: 699-712.
  15. Lau J.Y., Lai C.L., Lin H.J. et al. Fatal reactivation of chronic hepatitis B virus infection following withdraval of chemotherapy in lymphoma patients. Q. J. Med. 1989; 73: 911-917.
  16. Лопаткина Т.H. Латентная инфекция, вызванная вирусами гепатита В и С. Клин. гепатология 2009; 2: 3-8.
  17. Yeo W., Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220.
  18. Знойко O.O. Место нуклеоз(т)идных аналогов в лечении хронического гепатита В. Гепатологический форум 2010; 1: 11-21.
  19. Yeo W., Chan T.C., Leung N.W. et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J. Clin. Oncol. 2009; 27: 605-611.
  20. Niitsu N., Hagiwara Y., Tanae K. et al. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy. J. Clin. Oncol. 2010; 28: 5097-5100.
  21. Fukushima N., Mizuta T., Tanaka M. et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann. Oncol. 2009; 20: 2013-2017.
  22. Onozawa M., Hashino S., Izumiyama K. et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogenic hematopoetic stem cell transplantation in patients with previous hepatitis B infection. Transplantation 2005; 79: 616-619.
  23. Westhoff T.H., Jochimsen F., Schmittel A. et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930.
  24. Yeo W., Chan P.K., Hui P. et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J. Med.Virol. 2003; 70: 553-561.
  25. Dai M.S., Wu P.F., Shyu R.Y. et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int. 2004; 24: 540-564.
  26. ang J.W., Choi J.Y., Bae S. H. et al. Transarterial chemolipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J. Hepatol. 2004; 41: 427-435.
  27. Lau G.K., Leung Y.H., Fong D.Y. et al. et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood 2002; 99: 2324—2330.
  28. Weinbaum C.M. Todd D., Gerlich W.H. Recоmеndation for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm. Rep. 2008; 57: 1—20.
  29. Lau G.K., Yiu H.H., Fong D.Y. et al. Early is superior to deffered preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003; 125: 1742—1749.
  30. Hsu C., Chen H.L., Cheng A.L. et al. A revisit of prophylactic lamivudine for chemotherapy- associated hepatitis B reactivation in non-Hodgkin,s lymphomа: a randomized trial. Hepatology 2008; 47: 844—853.
  31. Loomba R., Rowley A., Wesley R. et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann. Intern. Med. 2008; 148: 519—528.
  32. Loomba R., Rowley A., Wesley R. et al. Pre — emptive lamivudine reduces the risk of chemotherapy-induced HBV — related morbidity and mortality in HBsAg-positive cancer patients: meta-analysis. Hepatology 2007; 46 (Suppl.): A945.
  33. Ziakas P.D., Karsaliakos P., Mylonakis E. Effect of prophylactic lamivudine for chemotherapy- associated hepatitis B reactivation in lymphoma: a meta-analysis of published clinical trials and a decision tree addressing prolonged prophylaxis and maintenance. Haematology 2009; 94: 998—1005.
  34. Aksoy S., Baden L.R., Marty F.M. et al. Rituximab — related viral infections in lymphoma patients. Leuk. Lymphoma, 2007; 48: 1307—1312.
  35. Targhetta C., Cabras M.G., Mamusa A.M. et al. Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo — or chemo-immune therapy. Haematologica 2008; 93: 951—952.
  36. Lau J.Y., Lai C.L., Lin H.J. et al. Fatal reactivation of chronic hepatitis B virus infection following withdraval of chemotherapy in lymphoma patients. Q. J. Med. 1989: 73: 911—917.
  37. Watanabe M., Shibuya A., Takada J. et al. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: A review of 16 patients. Eur. J. Intern. Med. 2010; 21: 333—337.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies